238 related articles for article (PubMed ID: 8515284)
1. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
[TBL] [Abstract][Full Text] [Related]
2. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
3. Effects of anandamide on cannabinoid receptors in rat brain membranes.
Childers SR; Sexton T; Roy MB
Biochem Pharmacol; 1994 Feb; 47(4):711-5. PubMed ID: 8129747
[TBL] [Abstract][Full Text] [Related]
4. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
5. Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Devane WA; Hanus L; Breuer A; Pertwee RG; Stevenson LA; Griffin G; Gibson D; Mandelbaum A; Etinger A; Mechoulam R
Science; 1992 Dec; 258(5090):1946-9. PubMed ID: 1470919
[TBL] [Abstract][Full Text] [Related]
6. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
Mackie K; Devane WA; Hille B
Mol Pharmacol; 1993 Sep; 44(3):498-503. PubMed ID: 8371711
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
8. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
9. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
[TBL] [Abstract][Full Text] [Related]
10. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat.
Weidenfeld J; Feldman S; Mechoulam R
Neuroendocrinology; 1994 Feb; 59(2):110-2. PubMed ID: 8127398
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
12. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
Fride E; Mechoulam R
Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
[TBL] [Abstract][Full Text] [Related]
14. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.
Deutsch DG; Chin SA
Biochem Pharmacol; 1993 Sep; 46(5):791-6. PubMed ID: 8373432
[TBL] [Abstract][Full Text] [Related]
16. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
Bonhaus DW; Chang LK; Kwan J; Martin GR
J Pharmacol Exp Ther; 1998 Dec; 287(3):884-8. PubMed ID: 9864268
[TBL] [Abstract][Full Text] [Related]
17. Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.
Christopoulos A; Wilson K
Brain Res; 2001 Oct; 915(1):70-8. PubMed ID: 11578621
[TBL] [Abstract][Full Text] [Related]
18. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors.
Melck D; Bisogno T; De Petrocellis L; Chuang H; Julius D; Bifulco M; Di Marzo V
Biochem Biophys Res Commun; 1999 Aug; 262(1):275-84. PubMed ID: 10448105
[TBL] [Abstract][Full Text] [Related]
19. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
Gómez del Pulgar T; Velasco G; Guzmán M
Biochem J; 2000 Apr; 347(Pt 2):369-73. PubMed ID: 10749665
[TBL] [Abstract][Full Text] [Related]
20. Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction.
Van der Kloot W
Brain Res; 1994 Jun; 649(1-2):181-4. PubMed ID: 7953630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]